Literature DB >> 2786473

The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment.

K C Carter1, G Gallagher, A J Baillie, J Alexander.   

Abstract

The ability of interleukin 4 (IL4), administered subcutaneously around the cutaneous lesion in the form of hydrophilic gels, to affect the development of established Leishmania major infections in the BALB/c mouse was studied. IL4 had a therapeutic effect on L. major lesion growth compared with control mice, causing not only resolution of the parasite lesions over a period of 10 weeks but also rendering animals resistant to reinfection. Adoptive transfer of splenic T cells, obtained from IL4-treated animals, conferred significant resistance to L. major infection in naive BALB/c mice compared with controls. These results demonstrate that IL4 is capable of not only reversing the usual (i.e. non-curing) course of L. major infection in the BALB/c mouse, but also of promoting the generation of protective immunity. The nature of the gel used to deliver the cytokine was found to be important since the therapeutic activity of IL4 in poloxamer gel was not observed when a hydroxypropylmethyl cellulose (hypromellose) gel was used as the IL4 vehicle.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786473     DOI: 10.1002/eji.1830190432

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Stimulation of antibacterial macrophage activities by B-cell stimulatory factor 2 (interleukin-6).

Authors:  I E Flesch; S H Kaufmann
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

2.  Inhibition of caspase-8 activity promotes protective Th1- and Th2-mediated immunity to Leishmania major infection.

Authors:  Wânia F Pereira-Manfro; Flávia L Ribeiro-Gomes; Alessandra Almeida Filardy; Natália S Vellozo; Landi V C Guillermo; Elisabeth M Silva; Richard M Siegel; George A Dosreis; Marcela F Lopes
Journal:  J Leukoc Biol       Date:  2013-09-26       Impact factor: 4.962

3.  Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution.

Authors:  W H Boom; L Liebster; A K Abbas; R G Titus
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  Increased expression of interleukin-4 receptors on psoriatic epidermal cells.

Authors:  E Prens; J Hegmans; R C Lien; R Debets; R Troost; T van Joost; R Benner
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.

Authors:  K C Carter; A J Baillie; A B Mullen
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

6.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

7.  Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis.

Authors:  G D Miralles; M Y Stoeckle; D F McDermott; F D Finkelman; H W Murray
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

8.  An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major.

Authors:  P B Kimsey; C M Theodos; T K Mitchen; S J Turco; R G Titus
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

9.  TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis.

Authors:  F Y Liew; Y Li; D M Yang; A Severn; F E Cox
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

10.  Evaluation of T cell responses in healing and nonhealing leishmaniasis reveals differences in T helper cell polarization ex vivo and in vitro.

Authors:  B-S Choi; P Kropf
Journal:  Parasite Immunol       Date:  2009-04       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.